Alkermes

Alkermes Sets Itself Up for a "Transformative" 2018
Motley Fool
Tue, 02/20/18 - 09:19 am
Alkermes
3 Biotech Stocks That Soared This Week
Motley Fool
Sun, 02/18/18 - 10:09 am
Alkermes
Immunogen
Sorrento Therapeutics
Alkermes hit with 3 gender discrimination lawsuits from former staffers
Fierce Pharma
Tue, 11/28/17 - 09:00 pm
Alkermes
gender discrimination
Alkermes shares rise 6% on Biogen multiple sclerosis drug partnership
Marketwatch
Mon, 11/27/17 - 09:10 am
Alkermes
Biogen
MS
multiple sclerosis
ALKS 8700
Alkermes touts equal efficacy of monthly Vivitrol against daily Suboxone
Endpoints
Wed, 11/15/17 - 08:58 pm
Alkermes
opioids
Vivitrol
Suboxone
Individor
Alkermes balks at U.S. senator’s probe into 'aggressive' Vivitrol lobbying and marketing
Fierce Pharma
Tue, 11/7/17 - 09:32 pm
Alkermes
Vivitrol
lobbying
Once-a-month shot for opioid addiction works as well as daily medication, study finds
Stat
Thu, 10/19/17 - 09:23 am
opioids
opioid addiction
Vivitrol
Alkermes
Suboxone
Will third trial be the charm for Alkermes' depression drug?
Fierce Biotech
Tue, 08/22/17 - 12:04 am
Alkermes
clinical trials
ALKS 5461
major depressive disorder
Alkermes Continues to Execute
Motley Fool
Fri, 07/28/17 - 11:27 am
Alkermes
earnings
Alkermes’ Vivitrol marketing and lobbying put it under gun; pharma says not fair
Fierce Pharma
Fri, 07/14/17 - 08:16 am
Alkermes
Vivitrol
drug marketing
lobbying
alcoholism
Alkermes says it's advancing 'full steam' with schizophrenia candidate
Fierce Biotech
Sat, 07/1/17 - 09:28 am
Alkermes
schizophrenia
ALKS 3831
Side Effect Weighs on Early Results for Alkermes’ Schizophrenia Drug
Xconomy
Fri, 06/30/17 - 09:40 am
Alkermes
schizophrenia
side effects
ALKS 3831
clinical trials
Alkermes claims a success in PhIII schizophrenia head-to-head, but where’s the benefit for patients?
Endpoints
Thu, 06/29/17 - 09:41 pm
Alkermes
schizophrenia
ALKS 3831
clinical trials
Can Alkermes' Latest Approval Spark a Rally?
Motley Fool
Wed, 06/7/17 - 11:25 am
Alkermes
drug approvals
Aristada
schizophrenia
Alkermes' Revenue Jumps 22%
Motley Fool
Mon, 05/1/17 - 11:34 am
Alkermes
earnings
Alkermes execs hit in the pocketbook, filing shows
BioPharma Dive
Mon, 04/17/17 - 11:15 am
Alkermes
executive pay
The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
TheStreet.com
Thu, 03/9/17 - 11:25 am
FDA
drug approvals
Alkermes
ALKS-5461
CytRx
aldoxorubicin
Dynavax Technologies
HEPLISAV-B
Intra-Cellular Therapies
ITI-007
Novan
SB204
Portola Pharmaceuticals
betrixaban
PTC Therapeutics
ataluren
Rigel Pharmaceuticals
fostamatinib
TG Therapeutics
ublituximab
Alkermes' Revenue Soars, Projects an Exciting Year Ahead
TheStreet.com
Thu, 02/16/17 - 10:08 am
Alkermes
earnings
Fresh enthusiasm for Cerecor sours as lead drug flops in PhII depression study, shares crater
Endpoints
Wed, 11/30/16 - 09:58 am
Cerecor
clinical depression
clinical trials
CERC-501
Eli Lilly
Alkermes
CNBC interviews Alkermes CEO about antidepressant comeback
Thu, 10/27/16 - 04:08 pm

Pages